GALACTIC HF

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction

Stadium
klaar
Middel
omecamtiv mecarbil
Populatie
Hartfalen
Fase
III
First Patient In
6 juli 2017
Last Patient In
28 juni 2019
Last Patient Last Visit
30 september 2020

National Lead

prof. dr. A. Voors

Cardioloog

Studiedirecteur

dr. J. Schaap

Cardioloog

De pagina is verlopen.